Premium
Finasteride in the Treatment of Benign Prostatic Hyperplasia. A Urodynamic Evaluation
Author(s) -
KIRBY R. S.,
BRYAN JENNY,
EARDLEY I.,
CHRISTMAS T. J.,
LIU S.,
HOLMES S. A. V.,
VALE J. A.,
SHANMUGANATHAN K.,
WEBB JUDITH A.
Publication year - 1992
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1992.tb15666.x
Subject(s) - finasteride , medicine , urology , placebo , hyperplasia , dihydrotestosterone , prostate , 5 alpha reductase inhibitor , placebo group , androgen , hormone , alternative medicine , pathology , cancer
Summary— A group of 69 men with bladder outflow obstruction due to benign prostatic hyperplasia (BPH) were treated in a double‐blind, placebo‐controlled study with finasteride (Proscar, MK‐906), a 5‐alpha reductase inhibitor, 5 mg or 10 mg/day or placebo for 3 months; subsequently, 20 patients received finasteride 5 mg/day for a further 9 months in an open extension study. In treated patients dihydrotestosterone declined by over 60%, remaining unchanged with placebo. Symptom scores fell significantly in all 3 groups. Mean maximum flow rates fell slightly in placebo‐treated patients but improved by 1.5 ml/s in the 10 mg group and by 3.3 ml/s in the 5 mg group. After 1 year's treatment, the reduction in symptom score and increase in flow rate were well maintained; the mean prostate volume was reduced by 14% and prostatic specific antigen declined by 28%. It was concluded that finasteride shows some efficacy in the treatment of BPH, with minimal toxicity, but 12 months of therapy or longer may be necessary to achieve maximal effect.